SCHEMBL6334335

SCHEMBL6334335

N#Cc1[nH]cnc1NC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 1/20 0.36
XDH P47989 4/20 0.33
GSK3B P49841 1/20 0.33
GAA P10253 3/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.31
TDP1 Q9NUW8 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
BRD4 O60885 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP3A5 P20815 1/20 0.31
MAPT P10636 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
POLB P06746 1/20 0.30
APEX1 P27695 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627107 0.84 MAPK8 (0.38) XDHGAAHSD17B10KDM4EALDH1A1
SCHEMBL7001612 0.81 XDH (0.43) XDHGAAHSD17B10KDM4EALDH1A1
SCHEMBL10821526 0.81 BRD4 (0.53) HSD17B10ALDH1A1BRD4SMN1; SMN2POLB
SCHEMBL6999635 0.79 XDH (0.50) XDHGSK3BALDH1A1
SCHEMBL10821714 0.77 XDH (0.58) XDHGSK3BKDM4EALDH1A1L3MBTL1
SCHEMBL10821581 0.77 GAA (0.46) GAACYP2C19KDM4EALDH1A1L3MBTL1
SCHEMBL10822025 0.76 MAPK1 (0.44) KDM4EALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL10821846 0.75 KMT2A (0.49) KDM4EALDH1A1BRD4SMN1; SMN2POLB
SCHEMBL6996417 0.75 XDH (0.62) XDHGSK3BALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL10821345 0.74 RAB9A (0.51) HSD17B10KDM4EALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 GABRR1 4068/4885XDH 2063/4885GSK3B 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.